OssDsign Marks 2,000-Patient Milestone for Bone Graft Product

OssDsign AB has treated 2,000 U.S. patients have with its nanosynthetic bone graft OssDsign Catalyst, doubling the number of cases in just four months. 

With 2,000 patients treated, OssDsign Catalyst continues to show exponential growth from earlier records of 1,000 treated patients in May and 500 patients treated in January. 
 
“It is great to see how our orthobiologics business continues its successful commercialization. The accelerating growth of OssDsign Catalyst shows that our differentiated innovation has received a broad market acceptance,” OssDsign CEO Morten Henneveld said.
 
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure that is resorbed and replaced by new and healthy bone tissue. The product was launched in the United States in August 2021. The U.S. Food and Drug Administration clearance is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion (the Boden model). OssDsign continues to gather clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry and TOP FUSION, in which patient enrolment was completed last year.
 
OssDsign develops and provides next-generation bone replacement products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in various orthopedic areas; its product portfolio consists of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries. The company has a strong commercial presence in the United States, Europe, and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.